News blog


  • BY: Andrew Hore |
  • POSTED: 12/03/2010 |

Skin treatments developer Syntopix has reduced the cash outflow from its operations in the six months to January 2010.

The interim cash outflow from operations fell from 736,000 to 498,000. The outflow is similar to the level in the second half of last year. Syntopix has reduced its research and development spending.

This leaves Syntopix with net cash of 396,000.

The outflow will have to fall sharply for that cash to last into next year. Syntopix says that it is finalising plans for a share issue. It mentioned the share issue in its 2008-09 figures published in January.

Syntopix continues to work with Procter & Gamble and is talking to other potential partners.

At 74p a share, up 3p on the day, Syntopix is valued at 5.71m. 

© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds